ES2525215T3 - Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado - Google Patents
Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado Download PDFInfo
- Publication number
- ES2525215T3 ES2525215T3 ES06746833.0T ES06746833T ES2525215T3 ES 2525215 T3 ES2525215 T3 ES 2525215T3 ES 06746833 T ES06746833 T ES 06746833T ES 2525215 T3 ES2525215 T3 ES 2525215T3
- Authority
- ES
- Spain
- Prior art keywords
- chiral
- optionally substituted
- brs
- nmr
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- INAXVFBXDYWQFN-XHSDSOJGSA-N morphinan Chemical group C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 64
- 229910052799 carbon Inorganic materials 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 3
- 239000001257 hydrogen Substances 0.000 abstract description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 4
- 125000005865 C2-C10alkynyl group Chemical group 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 74
- 239000000126 substance Substances 0.000 description 58
- 238000005481 NMR spectroscopy Methods 0.000 description 45
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 22
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 108700023159 delta Opioid Receptors Proteins 0.000 description 2
- 102000048124 delta Opioid Receptors Human genes 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- MDEQIPCZMDWUEN-UHFFFAOYSA-N methyl 2-(dimethylamino)acetate;hydrochloride Chemical compound Cl.COC(=O)CN(C)C MDEQIPCZMDWUEN-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005151864 | 2005-05-25 | ||
| JP2005151864 | 2005-05-25 | ||
| JP2006065762 | 2006-03-10 | ||
| JP2006065762 | 2006-03-10 | ||
| WOPCT/JP2006/310231 | 2006-05-23 | ||
| PCT/JP2006/310231 WO2006126529A1 (ja) | 2005-05-25 | 2006-05-23 | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| PCT/JP2006/310454 WO2006126637A1 (ja) | 2005-05-25 | 2006-05-25 | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2525215T3 true ES2525215T3 (es) | 2014-12-19 |
Family
ID=37451954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06746833.0T Active ES2525215T3 (es) | 2005-05-25 | 2006-05-25 | Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8084460B2 (Direct) |
| EP (1) | EP1889848B8 (Direct) |
| JP (1) | JP4323547B2 (Direct) |
| KR (1) | KR100912782B1 (Direct) |
| CN (1) | CN101228172B (Direct) |
| AU (1) | AU2006250390B2 (Direct) |
| BE (1) | BE2019C533I2 (Direct) |
| BR (1) | BRPI0610343B8 (Direct) |
| CA (1) | CA2609733C (Direct) |
| DK (1) | DK1889848T3 (Direct) |
| ES (1) | ES2525215T3 (Direct) |
| FR (1) | FR19C1042I2 (Direct) |
| HU (1) | HUS1900034I1 (Direct) |
| MX (1) | MX2007014588A (Direct) |
| NL (1) | NL300996I2 (Direct) |
| PL (1) | PL1889848T3 (Direct) |
| PT (1) | PT1889848E (Direct) |
| RU (1) | RU2403255C2 (Direct) |
| TW (1) | TWI311056B (Direct) |
| WO (2) | WO2006126529A1 (Direct) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| US8173666B2 (en) | 2007-03-12 | 2012-05-08 | Nektar Therapeutics | Oligomer-opioid agonist conjugates |
| US10512644B2 (en) | 2007-03-12 | 2019-12-24 | Inheris Pharmaceuticals, Inc. | Oligomer-opioid agonist conjugates |
| CA2905541C (en) * | 2008-01-09 | 2020-02-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| JP5252391B2 (ja) * | 2008-02-21 | 2013-07-31 | 学校法人北里研究所 | オキサビシクロ［２．２．２］オクタンを有するモルヒナン誘導体およびその医薬用途 |
| CA2734333A1 (en) * | 2008-09-16 | 2010-03-25 | Nektar Therapeutics | Pegylated opioids with low potential for abuse |
| BR112012006069A8 (pt) * | 2009-09-18 | 2017-10-10 | Adolor Corp | Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto |
| US20130217672A1 (en) * | 2010-05-13 | 2013-08-22 | Green Cross Corporation | (+)-3-hydroxymorphinan-based polycycle derivatives |
| US9108975B2 (en) | 2010-11-12 | 2015-08-18 | Shionogi & Co., Ltd. | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
| US10952968B2 (en) | 2012-05-14 | 2021-03-23 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
| CN110325178B (zh) * | 2016-12-26 | 2022-05-13 | 盐野义制药株式会社 | 改善含量均一性的制剂的制造方法 |
| MA52249A (fr) | 2018-04-12 | 2021-05-05 | Morphic Therapeutic Inc | Antagonistes de l'intégrine humaine (alpha4) (beta7) |
| KR102201609B1 (ko) | 2019-04-19 | 2021-01-12 | 연성정밀화학(주) | 날데메딘의 제조방법 |
| ES3035561T3 (en) | 2019-10-16 | 2025-09-04 | Morphic Therapeutic Inc | Inhibiting human integrin alpha4beta7 |
| EP4062973A4 (en) | 2019-11-20 | 2023-11-29 | Shionogi & Co., Ltd | 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation |
| CN111905111B (zh) * | 2020-09-16 | 2023-03-31 | 地奥集团成都药业股份有限公司 | 一种评价复方谷氨酰胺组方对腹泻型肠易激综合征疗效的方法 |
| IT202300009864A1 (it) * | 2023-05-16 | 2024-11-16 | Procos Spa | Processo per la preparazione di naldemedina |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4272541A (en) | 1978-06-02 | 1981-06-09 | Miles Laboratories, Inc. | 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them |
| US4275205A (en) | 1980-05-05 | 1981-06-23 | Miles Laboratories, Inc. | 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols |
| US4347361A (en) | 1980-12-10 | 1982-08-31 | Sisa, Incorporated | 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds |
| US4370333A (en) | 1981-06-29 | 1983-01-25 | Sisa, Incorporated | 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it |
| US4443605A (en) | 1982-07-30 | 1984-04-17 | Miles Laboratories, Inc. | 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans |
| US4440932A (en) | 1982-09-09 | 1984-04-03 | Miles Laboratories, Inc. | 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans |
| US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
| WO1995003308A1 (fr) | 1993-07-23 | 1995-02-02 | Toray Industries, Inc. | Derive de morphinane et application medicale |
| US5464841A (en) | 1993-11-08 | 1995-11-07 | Univ Minnesota | Use of delta opioid receptor antagonists to treat immunoregulatory disorders |
| KR19990077125A (ko) | 1996-01-10 | 1999-10-25 | 파올로 비지, 엔리꼬 카쭐라니 | 헤테로고리-축합 모르핀 유도체 (ⅱ) |
| WO2001002375A1 (en) | 1999-07-01 | 2001-01-11 | Chemrx Advanced Technologies, Inc. | Process for synthesizing oxadiazoles |
| US6451806B2 (en) * | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| AU784541B2 (en) * | 1999-11-29 | 2006-04-27 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
| US20040024004A1 (en) | 2001-05-04 | 2004-02-05 | Sherman Barry M. | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
| EP1284736A2 (en) | 2000-05-05 | 2003-02-26 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
| WO2001085150A2 (en) | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists |
| ES2239170T3 (es) * | 2000-10-31 | 2005-09-16 | Rensselaer Polytechnic Institute | 2,6-metano-3-benzazocinas sustituidas en posicion 8 y morfinanos sustituidos en posicion 3 como agentes ligantes a receptores opioides. |
| JP4292738B2 (ja) * | 2000-11-22 | 2009-07-08 | 東レ株式会社 | インドール誘導体およびその医薬用途 |
| ATE466016T1 (de) * | 2001-08-23 | 2010-05-15 | Organon Nv | Verfahren for zur herstellung eines 14- hydroxynormorphinon-derivats |
| DE10161963A1 (de) | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung |
| DE10229842A1 (de) * | 2002-07-03 | 2004-02-05 | Helmut Prof. Dr. Schmidhammer | Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung |
| EP1522542A1 (en) * | 2002-07-11 | 2005-04-13 | Toray Industries, Inc. | Therapeutic or preventive agent for nausea/vomiting |
| AU2003299045A1 (en) * | 2002-09-18 | 2004-04-08 | The Curators Of The University Of Missouri | OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR |
| US20040157784A1 (en) | 2003-02-10 | 2004-08-12 | Jame Fine Chemicals, Inc. | Opiod tannate compositions |
| WO2005105093A2 (en) | 2003-08-26 | 2005-11-10 | Duke University | METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION |
| US8481501B2 (en) | 2004-05-28 | 2013-07-09 | Human Biomolecular Research Institute | Synthesis of metabolically stable analgesics, pain medications and other agents |
| US20060063792A1 (en) | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| US7142420B2 (en) | 2004-09-20 | 2006-11-28 | Qualcomm, Incorporated | Devices and methods for controlling relative movement between layers of an electronic device |
| WO2006126529A1 (ja) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体 |
| US9108975B2 (en) | 2010-11-12 | 2015-08-18 | Shionogi & Co., Ltd. | Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same |
-
2006
- 2006-05-23 WO PCT/JP2006/310231 patent/WO2006126529A1/ja not_active Ceased
- 2006-05-24 TW TW095118443A patent/TWI311056B/zh active
- 2006-05-25 ES ES06746833.0T patent/ES2525215T3/es active Active
- 2006-05-25 DK DK06746833.0T patent/DK1889848T3/en active
- 2006-05-25 PL PL06746833T patent/PL1889848T3/pl unknown
- 2006-05-25 CA CA2609733A patent/CA2609733C/en active Active
- 2006-05-25 WO PCT/JP2006/310454 patent/WO2006126637A1/ja not_active Ceased
- 2006-05-25 BR BRPI0610343A patent/BRPI0610343B8/pt not_active IP Right Cessation
- 2006-05-25 CN CN2006800271187A patent/CN101228172B/zh active Active
- 2006-05-25 US US11/920,851 patent/US8084460B2/en not_active Ceased
- 2006-05-25 EP EP06746833.0A patent/EP1889848B8/en active Active
- 2006-05-25 US US15/064,511 patent/USRE46365E1/en active Active
- 2006-05-25 PT PT67468330T patent/PT1889848E/pt unknown
- 2006-05-25 MX MX2007014588A patent/MX2007014588A/es active IP Right Grant
- 2006-05-25 RU RU2007148412/04A patent/RU2403255C2/ru active
- 2006-05-25 AU AU2006250390A patent/AU2006250390B2/en not_active Ceased
- 2006-05-25 JP JP2007517895A patent/JP4323547B2/ja active Active
-
2007
- 2007-11-23 KR KR1020077027287A patent/KR100912782B1/ko active Active
-
2011
- 2011-11-30 US US13/308,483 patent/US8536192B2/en not_active Ceased
-
2016
- 2016-03-08 US US15/064,538 patent/USRE46375E1/en active Active
-
2019
- 2019-06-20 FR FR19C1042C patent/FR19C1042I2/fr active Active
- 2019-06-24 BE BE2019C533C patent/BE2019C533I2/nl unknown
- 2019-06-26 NL NL300996C patent/NL300996I2/nl unknown
- 2019-07-03 HU HUS1900034C patent/HUS1900034I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2525215T3 (es) | Derivado morfinano sustituido con 7-carbamoilo-6,7-insaturado | |
| EP3820574B1 (en) | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases | |
| EP3672949B1 (en) | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
| EP3885342B1 (en) | Bicyclic inhibitors of pad4 | |
| EP2520567A2 (en) | Nitrogen-containing heterocycle derivatives substituted with cyclic group | |
| US9630922B2 (en) | 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors | |
| RU2475488C2 (ru) | Дигидродиазепины, которые можно использовать в качестве ингибиторов протеинкиназ | |
| CN102955359A (zh) | 盐、光致抗蚀剂组合物和用于制备光致抗蚀剂图案的方法 | |
| CN101420955B (zh) | 可用作蛋白激酶抑制剂的二氢二氮杂* | |
| CN101678022A (zh) | 可用作蛋白激酶抑制剂的5-氰基-4-(吡咯并[2,3b]吡啶-3-基)嘧啶衍生物 | |
| US20250163049A1 (en) | Fused bicyclic heterocyclyl compounds as usp1 inhibitors | |
| US6765096B1 (en) | Tricyclic compound having acyloxymethoxycarbonyl side chain | |
| US20180360803A1 (en) | Pharmaceutical composition for treatment or prevention of nash | |
| ES2561298T3 (es) | Compuestos de aminometilquinolona | |
| US6103732A (en) | Carboxylic acid derivatives, their production and use | |
| US12177971B2 (en) | Wiring board | |
| JP4737495B2 (ja) | エリスロマイシン誘導体 | |
| ES2447891T3 (es) | Procedimiento para la preparación de beta-cetonitrilos | |
| US20250170126A1 (en) | Novel b0at1 inhibitor | |
| US20040034076A1 (en) | Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists | |
| RU2795850C2 (ru) | Производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения | |
| HK1129298B (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
| HK1142267A (en) | 5-cyan0-4- (pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |